Member Info for Cliveas

Plenty of large disguised trades leads me to believe positions are being taken and await relevant tr1's.

GL.

1.1m as of 31/03/23.

Don't think placing is imminent as they have taken action to preserve and even grow cash :

Company continues to trade in line with expectations underpinned by a strong order book and pipeline of potential new business;

Following a 23% reduction in administrative costs including staffing expenses, the net cash used in operating activities declined by 58% in the first half, putting the Company on track for a substantially lower cash burn for the full year;

Second half revenues are expected to show further growth compared with the corresponding period in the previous year;

In January, Guild Esports committed to adding 2 million new followers to its owned audience. After seeing success across the first three months of 2023, Guild has upgraded this audience growth estimate to 5 million.

GL.

1.1m net cash

Costs reduced 58%

Revenues to increase H2.

Not that bad at all!

GL.

I believe an approach will be forthcoming very soon.

GL.

Gonna pop so had a punt!

GL.

Poster trying far too hard imho!

GL.

They have 9m in the bank.

So how do you base your 1p target? ( facts please)

GL.

Mcap now less than cash so if they just shut up shop and returned cash to shareholders it would be north of here.

GL.

The yanks are coming!
The yanks are coming!
Going to buy us out for a pound!
LOL.

GL.

Also Medicare/Medicaid approval expected in Q2 ie by at least end of june!

Following the successful progression of the Company's laboratory registration status to Compliance Certification by the Centers for Medicare & Medicaid ('CMS'), allowing its commercial operation for samples received from patients in 45 US states, Verici Dx is ready to build on the initial rollout activity over the course of 2023. Medicare and Medicaid account nationally for about 65% of all transplant patients and the Company is focused the initial rollout of the test where the proportion of Medicare patients is higher than the national average. To further drive adoption the Company has addressed the pricing and coverage determinations under Medicare. This is administered by the MolDx region of Palmetto given the Company's laboratory is based in Tennesse. The Company submitted its pricing proposal in Q1 2023 and expects to get the MolDx pricing recommendation by the end of Q2 2023. The Company is currently preparing its submission for Medicare insurance reimbursement coverage, under the Local Coverage Determination (LCD) offered in Palmetto and a coverage determination is expected later this year. Registration for Medicaid has been approved in three states and submitted in a further 11 states as well as with BlueCross Blue Shield of Tennessee, the largest health benefit plan company in the state.

GL.

The only lemming I see is someone posting whilst on holiday!

Put some sunscreen on and relax FFS.

GL.

Looks like MM looking to shake when really its good news.

Beware of stoplosses.

GL.

One sponsor out early but great new sponsor in!
1.28m in the bank.
Lets hope its the start of regular newsflow!

GL.

RNS 5/01/22.

GL.

We'll see if they come knocking.
Now turn off your caps lock and calm down.

GL.

Shows you know F all about the market VRCI are in or their competitors PAL.

GL.

Care dx seem to have been hit the hardest in the US re changes in insurance reimbursement.

From a post on advfn :

CareDx: Rocked By Uncertainty
Apr. 21, 2023

Today, we put CareDx, Inc (NASDAQ:CDNA) in the spotlight for the first time ever. The stock plunged some 30% in early March after an analyst at Stephens warned that 'a new billing and coding document published by the Centers for Medicare and Medicaid Services [CMS] "appeared clearly negative" for CareDx. The stock has also dropped an additional just over 15% since then.

Full article - hTTps://seekingalpha.com/article/4595674-caredx-rocked-by-uncertainty

Slight delay to include clarava results I presume.

Expect them to be good or why would you delay?

Again fully funded until mid 2024.

GL.

Approved USA refund due this qtr!
GL.

Nice volume still very cheap!
Defo takeover target!

??GL.